Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype.

Matter MS, Marquardt JU, Andersen JB, Quintavalle C, Korokhov N, Stauffer JK, Kaji K, Decaens T, Quagliata L, Elloumi F, Hoang T, Molinolo A, Conner EA, Weber A, Heikenwalder M, Factor VM, Thorgeirsson SS.

Hepatology. 2016 Jun;63(6):1888-99. doi: 10.1002/hep.28487. Epub 2016 Mar 15.

2.

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours.

Scarzello AJ, Jiang Q, Back T, Dang H, Hodge D, Hanson C, Subleski J, Weiss JM, Stauffer JK, Chaisaingmongkol J, Rabibhadana S, Ruchirawat M, Ortaldo J, Wang XW, Norris PS, Ware CF, Wiltrout RH.

Gut. 2016 Oct;65(10):1765-75. doi: 10.1136/gutjnl-2014-308810. Epub 2015 Jul 23.

3.

Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.

Subleski JJ, Scarzello AJ, Alvord WG, Jiang Q, Stauffer JK, Kronfli A, Saleh B, Back T, Weiss JM, Wiltrout RH.

J Hepatol. 2015 Nov;63(5):1181-9. doi: 10.1016/j.jhep.2015.06.021. Epub 2015 Jul 2.

4.

CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.

Weiss JM, Gregory Alvord W, Quiñones OA, Stauffer JK, Wiltrout RH.

Hum Immunol. 2014 Jul;75(7):614-20. doi: 10.1016/j.humimm.2014.04.018. Epub 2014 May 4.

PMID:
24801648
5.

Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence.

Tang Y, Horikawa I, Ajiro M, Robles AI, Fujita K, Mondal AM, Stauffer JK, Zheng ZM, Harris CC.

Oncogene. 2013 May 30;32(22):2792-8. doi: 10.1038/onc.2012.288. Epub 2012 Jul 9.

PMID:
22777358
6.

High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.

Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, Hixon JA, Back TC, Wei JS, Patidar R, Song Y, Hurd L, Tsokos M, Lai EW, Eisenhofer G, Weiss W, Khan J, Wigginton JM.

Cancer Invest. 2012 Jun;30(5):343-63. doi: 10.3109/07357907.2012.664670.

PMID:
22571338
7.

Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections.

Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH.

Hepatology. 2012 Oct;56(4):1567-74. doi: 10.1002/hep.25674. Epub 2012 Sep 11. Review.

8.

Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.

Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH.

Cancer Res. 2011 Apr 1;71(7):2718-27. doi: 10.1158/0008-5472.CAN-10-2705. Epub 2011 Feb 15.

9.

Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.

Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19455-60. doi: 10.1073/pnas.0909474106. Epub 2009 Nov 5.

10.

Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.

Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, Dai RM, Scheetz L, Lincoln E, Back TC, Powell D, Hurwitz AA, Sayers TJ, Kastelein R, Pavlakis GN, Felber BK, Trinchieri G, Wigginton JM.

J Immunol. 2009 Apr 1;182(7):4328-38. doi: 10.4049/jimmunol.0800471.

11.

Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.

Khan T, Stauffer JK, Williams R, Hixon JA, Salcedo R, Lincoln E, Back TC, Powell D, Lockett S, Arnold AC, Sayers TJ, Wigginton JM.

J Immunol. 2006 May 15;176(10):6302-12.

12.

Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors.

Stauffer JK, Khan T, Salcedo R, Hixon JA, Lincoln E, Back TC, Wigginton JM.

J Immunother. 2006 Mar-Apr;29(2):151-64.

PMID:
16531816
13.

Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma.

Khan T, Hixon JA, Stauffer JK, Lincoln E, Back TC, Brenner J, Lockett S, Nagashima K, Powell D, Wigginton JM.

J Natl Cancer Inst. 2006 Feb 1;98(3):190-202.

PMID:
16449679
14.

IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.

Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM.

J Immunol. 2004 Dec 15;173(12):7170-82.

15.

Structure and promoter analysis of the human unc-33-like phosphoprotein gene. E-box required for maximal expression in neuroblastoma and myoblasts.

Matsuo T, Stauffer JK, Walker RL, Meltzer P, Thiele CJ.

J Biol Chem. 2000 Jun 2;275(22):16560-8. Erratum in: J Biol Chem 2000 Aug 11;275(32):25052-3.

16.
17.

Unique use of alternative polyadenylation signals in the mouse aldolase B gene.

Maine AB, Stauffer JK, Tolan DR, Ciejek-Baez E.

Biochim Biophys Acta. 1992 Jan 6;1129(2):243-5.

PMID:
1730064
18.

Nonconservative utilization of aldolase A alternative promoters.

Stauffer JK, Colbert MC, Ciejek-Baez E.

J Biol Chem. 1990 Jul 15;265(20):11773-82.

Supplemental Content

Loading ...
Support Center